Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence

被引：8

作者：

Bogina, Giuseppe ^{[1
]}

Lunardi, Gianluigi ^{[1
]}

Coati, Francesca ^{[1
]}

Zamboni, Giuseppe ^{[1
]}

Gori, Stefania ^{[1
]}

Bortesi, Laura ^{[1
]}

Marconi, Marcella ^{[1
]}

Cassandrini, Paola Agnese ^{[1
]}

Turazza, Monica ^{[1
]}

Cortesi, Laura ^{[2
]}

DeMatteis, Elisabetta ^{[2
]}

Ficarra, Guido ^{[2
]}

Ibrahim, Toni ^{[3
]}

Serra, Patrizia ^{[3
]}

Medri, Laura ^{[4
]}

Giraudi, Sara ^{[5
]}

Lambertini, Matteo ^{[5
]}

Carli, Franca ^{[5
]}

Foglietta, Jennifer ^{[6
]}

Sidoni, Angelo ^{[7
]}

Nunzi, Martina ^{[8
]}

Ficorella, Corrado ^{[9
]}

Diadema, Maria Rosaria ^{[10
]}

Del Mastro, Lucia ^{[5
]}

机构：

[1] Sacro Cuore Don Calabria Hosp Negrar, Verona, Italy

[2] Univ Modena & Reggio Emilia, Modena, Italy

[3] Ist Sci Romagnolo Cura Tumori Meldola, Forli, Italy

[4] Morgagni Pierantoni Hosp, Forli, Italy

[5] IRCCS AOU San Martino IST, Genoa, Italy

[6] Azienda Osped Perugia, Perugia, Italy

[7] Univ Perugia, I-06100 Perugia, Italy

[8] AO Santa Maria, Terni, Italy

[9] Univ Aquila, San Salvatore Hosp, I-67100 Laquila, Italy

[10] Univ Naples 2, Naples, Italy

来源：

TUMORI JOURNAL | 2015年 / 101卷 / 04期

关键词：

Breast cancer; Locoregional recurrence; Metastasis; Progesterone receptor; PROGNOSTIC IMPACT; TAMOXIFEN; DISCORDANCE; EXPRESSION;

D O I：

10.5301/tj.5000323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos. Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.

引用

页码：398 / 403

页数：6

共 30 条

[1] Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial [J].

Aebi, Stefan ;

Gelber, Shari ;

Anderson, Stewart J. ;

Lang, Istvan ;

Robidoux, Andre ;

Martin, Miguel ;

Nortier, Johan W. R. ;

Paterson, Alexander H. G. ;

Rimawi, Mothaffar F. ;

Canada, Jose Manuel Baena ;

Thuerlimann, Beat ;

Murray, Elizabeth ;

Mamounas, Eleftherios P. ;

Geyer, Charles E., Jr. ;

Price, Karen N. ;

Coates, Alan S. ;

Gelber, Richard D. ;

Rastogi, Priya ;

Wolmark, Norman ;

Wapnir, Irene L. .

LANCET ONCOLOGY, 2014, 15 (02) :156-163

[2] Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? [J].

Allison, K. H. ;

Kandalaft, P. L. ;

Sitlani, C. M. ;

Dintzis, S. M. ;

Gown, A. M. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :413-424

[3] Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].

Amir, Eitan ;

Miller, Naomi ;

Geddie, William ;

Freedman, Orit ;

Kassam, Farrah ;

Simmons, Christine ;

Oldfield, Maria ;

Dranitsaris, George ;

Tomlinson, George ;

Laupacis, Andreas ;

Tannock, Ian F. ;

Clemons, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592

[4] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].

Arpino, G ;

Weiss, H ;

Lee, AV ;

Schiff, R ;

De Placido, S ;

Osborne, CK ;

Elledge, RM .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261

[5]

Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1

[6] Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial [J].

Bartlett, John M. S. ;

Brookes, Cassandra L. ;

Robson, Tammy ;

van de Velde, Cornelis J. H. ;

Billingham, Lucinda J. ;

Campbell, Fiona M. ;

Grant, Margaret ;

Hasenburg, Annette ;

Hille, Elysee T. M. ;

Kay, Charlene ;

Kieback, Dirk G. ;

Putter, Hein ;

Markopoulos, Christos ;

Kranenbarg, Elma Meershoek-Klein ;

Mallon, Elizabeth A. ;

Dirix, Luc ;

Seynaeve, Caroline ;

Rea, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1531-1538

[7] Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss [J].

Bogina, Giuseppe ;

Bortesi, Laura ;

Marconi, Marcella ;

Venturini, Marco ;

Lunardi, Gianluigi ;

Coati, Francesca ;

Massocco, Alberto ;

Manfrin, Erminia ;

Pegoraro, Cristina ;

Zamboni, Giuseppe .

VIRCHOWS ARCHIV, 2011, 459 (01) :1-10

[8] Progesterone receptor loss Identifies Luminal B breast cancer subgroups at higher risk of relapse [J].

Cancello, G. ;

Maisonneuve, P. ;

Rotmensz, N. ;

Viale, G. ;

Mastropasqua, M. G. ;

Pruneri, G. ;

Montagna, E. ;

Iorfida, M. ;

Mazza, M. ;

Balduzzi, A. ;

Veronesi, P. ;

Luini, A. ;

Intra, M. ;

Goldhirsch, A. ;

Colleoni, M. .

ANNALS OF ONCOLOGY, 2013, 24 (03) :661-668

[9] Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Fallowfield, L. ;

Costa, A. ;

Castiglione, M. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2011, 22 :vi25-vi30

[10]

Clark BZ, 2013, APPL IMMUNOHISTO M M, V21, P287, DOI 10.1097/PAI.0b013e31826f80c9

← 1 2 3 →